Regulatory (FOXP3+) T cells as target for immune therapy of cervical intraepithelial neoplasia and cervical cancer

Cancer Science

Volumn 100, Issue 6, 2009, Pages 1112-1117

  Loddenkemper, Christoph ^a   Hoffmann, Corinna ^a   Stanke, Jonas ^a   Nagorsen, Dirk ^a   Baron, Udo ^a   Olek, Sven ^a   Huehn, Jochen ^b   Ritz, Joerg Peter ^c   Stein, Harald ^a   Kaufmann, Andreas M ^a   Schneider, Achim ^a   Cichon, Günter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b EPIONTIS GMBH   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR ANTIBODY; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G2B KAPPA ANTIBODY; RECEPTOR ANTIBODY; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; CD3 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR RECEPTOR; TNFRSF18 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INVASION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; COLON CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LUNG CARCINOMA; LYMPHOCYTIC INFILTRATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; TARGET CELL; TUMOR IMMUNITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; ANIMAL; DNA METHYLATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; PATHOLOGY; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; UTERINE CERVIX TUMOR; VIRUS INFECTION; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA METHYLATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; PAPILLOMAVIRUS INFECTIONS; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HETEROLOGOUS; UTERINE CERVICAL NEOPLASMS;

EID: 67649848116     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01153.x     Document Type: Article

References (45)

1. Crispin JC, Martinez A, Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2003, 21:273-6.
2. Kukreja A, Cost G, Marker J. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002, 109:131-40.
3. Cao D, van Vollenhoven R, Klareskog L, Trollmo C, Malmstrom V. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther 2004, 6:R335-46.
4. de Kleer IM, Wedderburn LR, Taams LS. CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 2004, 172:6435-43.
5. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004, 199:971-9.
6. Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 2005, 54:369-77.
7. Woo EY, Chu CS, Goletz TJ. Regulatory CD4 (+) CD25 (+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001, 61:4766-72.
8. Liyanage UK, Moore TT, Joo HG. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002, 169:2756-61.
9. Viguier M, Lemaitre F, Verola O. Foxp3 expressing CD4+CD25 (high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004, 173:1444-53.
10. Yu P, Lee Y, Liu W. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005, 201:779-91.
11. Imai H, Saio M, Nonaka K. Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci 2007, 98:416-23.
12. Viehl CT, Moore TT, Liyanage UK. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol 2006, 13:1252-8.
13. Comes A, Rosso O, Orengo AM. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J Immunol 2006, 176:1750-8.
14. Nagai H, Horikawa T, Hara I. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp Dermatol 2004, 13:613-20.
15. Jones E, Dahm-Vicker M, Simon AK. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2002, 2:1.
16. Zheng Y, Rudensky AY. Foxp3 in control of the regulatory T cell lineage. Nat Immunol 2007, 8:457-62.
17. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-61.
18. Floess S, Freyer J, Siewert C. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007, 5:e38.
19. Baron U, Floess S, Wieczorek G. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3 (+) conventional T cells. Eur J Immunol 2007, 37:2378-89.
20. Polansky JK, Kretschmer K, Freyer J. DNA methylation controls Foxp3 gene expression 3. Eur J Immunol 2008, 38:1654-63.
21. Huehn J, Polansky JK, Hamann A. Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage?. Nat Rev Immunol 2009, 9:83-9.
22. Huehn J, Hamann A. Homing to suppress: address codes for Treg migration. Trends Immunol 2005, 26:632-6.
23. Bayry J, Triebel F, Kaveri SV, Tough DF. Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells. J Immunol 2007, 178:4184-93.
24. Clark RA, Kupper TS. IL-15 and dermal fibroblasts induce proliferation of natural regulatory T cells isolated from human skin. Blood 2007, 109:194-202.
25. Ko K, Yamazaki S, Nakamura K. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 2005, 202:885-91.
26. Kaufmann AM, Nieland JD, Jochmus I. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer 2007, 121:2794-800.
27. Fiander AN, Tristram AJ, Davidson EJ. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer 2006, 16:1075-81.
28. Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 2006, 13:592-7.
29. Frazer IH, Quinn M, Nicklin JL. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 2004, 23:172-81.
30. Hallez S, Simon P, Maudoux F. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother 2004, 53:642-50.
31. Sheets EE, Urban RG, Crum CP. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16, E7 plasmid DNA. J Obstet Gynecol 2003, 181:916-26.
32. de Jong A, O'Neill T, Khan AY. Enhancement of human papillomavirus (HPV) type 16, E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 2002, 20:3456-64.
33. Muderspach L, Wilczynski S, Roman L. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000, 6:3406-16.
34. Santin AD, Bellone S, Palmieri M. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. Gynecol Oncol 2003, 89:271-80.
35. Ferrara A, Nonn M, Sehr P. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 2003, 129:521-30.
36. Wieczorek G, Asemissen A, Model F. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 2009, 69:599-608.
37. Loddenkemper C, Schernus M, Noutsias M, Stein H, Thiel E, Nagorsen D. In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer. J Transl Med 2006, 4:52.
38. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999, 59:3128-33.
39. Nocentini G, Riccardi C. GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily. Eur J Immunol 2005, 35:1016-22.
40. Cohen AD, Diab A, Perales MA. Agonist anti-GITR antibody enhances vaccine-induced CD8 (+) T-cell responses and tumor immunity. Cancer Res 2006, 66:4904-12.
41. Ko HJ, Kim YJ, Kim YS. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 2007, 67:7477-86.
42. Tuyaerts S, Van Meirvenne S, Bonehill A. Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells. J Leukoc Biol 2007, 82:93-105.
43. Baltz KM, Krusch M, Bringmann A. Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J 2007, 21:2442-54.
44. Powell DJ, Felipe-Silva A, Merino MJ. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol 2007, 179:4919-28.
45. Dannull J, Su Z, Rizzieri D. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005, 115:3623-33.